-+ 0.00%
-+ 0.00%
-+ 0.00%

VOYAGER ASGCT LATE BREAKER: SINGLE IV DOSE OF VY1706 WELL TOLERATED, REDUCED TAU IN 3-MONTH GLP TOXICOLOGY DATA; CLINICAL TRIAL IN ALZHEIMER’S DISEASE EXPECTED H2 2026

Reuters·05/13/2026 10:01:00

Please log in to view news